Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

St Gallen Consensus 2009: A Radically Different Approach To Treating Early Breast Cancer
A radically different approach to choosing the best treatment options for early breast cancer has been proposed by an international panel of experts in a report from the 11th St Gallen conference.
generic viagra online
Prospective Clinical Advantages Of Trabecular Metal(TM) Technology Highlighted In Comparative Study
Zimmer Holdings, Inc. (NYSE: ZMH; SWX: ZMH) announced that data from a comparative clinical study conducted by researchers at the Mayo Clinic and the Joint Replacement Surgeons of the Indiana Research Foundation describes the low stiffness and osteoconductive properties of Zimmer"s Trabecular Metal Technology. The study, published in The Journal of Arthroplasty, found significant reductions in acetabular bone loss adjacent to the Trabecular Metal device compared to the titanium component, and a significant relative increase in bone mineral density (BMD) after total hip arthroplasty (THA) using implants made with Zimmer"s proprietary Trabecular Metal Technology.
News of the day
Shire Announces Study Results Of The Effects Of INTUNIV™ Extended Release On Secondary Measures In Children With ADHD And Oppositional Symptoms
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced new findings on INTUNIV (guanfacine) extended release, a selective alpha-2A-agonist, at a major psychiatric meeting. This randomized placebo controlled trial met its primary objective, which was to evaluate the effects of INTUNIV on oppositional symptoms in children aged 6 to 12 years with a diagnosis of ADHD and the presence of oppositional symptoms. The data presented today on this investigational compound reviewed secondary efficacy measures from three different rating scales.
Health Insurance

Link Between Breast Cancer Hormone Receptor Status And Risk Of A Second Primary Tumor

Women with hormone receptor (HR) negative first tumors have twice as much risk for developing a second breast cancer as women with HR-positive tumors, according to a study published online July 9 in the Journal of the National Cancer Institute. Christina A. Clarke, Ph.D., of the Northern California Cancer Center in Fremont, Calif., and colleagues examined data from the National Cancer Institute"s Surveillance, Epidemiology, and End Results database to analyze whether a first tumor"s estrogen receptor and progesterone receptor content and the age or race of the woman has anything to do with her risk of a second tumor. They found that women who have had breast cancer are at increased risk of a second primary breast cancer, compared with risk in the general population. They also found that women whose first tumors were hormone-receptor negative, compared with those whose tumors were hormone-receptor positive, had almost twice as much risk of any second breast cancer, and a five-fold increase in risk of a second hormone-receptor negative breast cancer. "Future research should focus on identifying genetic factors that predispose women to multiple HR-negative tumors to target screening, prevention, and treatment strategies more effectively," the author writes. Steve Graff Journal of the National Cancer Institute


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009